Dercum’s Disease Market Insights to Record Exponential Growth Owing To High Demand By 2030

The industry will undoubtedly expand due to non-invasive diagnostic techniques like ultrasound therapy.

Dercum’s disease market insights and analysis by treatment, by distribution channel, by end user - forecast till 2030. Adiposis dolorosa, another name for Dercum's disease, is a condition marked by a number of lipomas. Lipomas are situated beneath the epidermis and can be painful to the touch in varying degrees. The trunk, upper arms, and upper legs are typically affected. Market Research Future (MRFR) presents drivers, opportunities, and obstacles in great detail in its study on the Dercum's disease market.

Market Outlook

The market for treatments for Dercum's disease is anticipated to reach a record high by growing at a CAGR of 6.10% between 2022 and 2030. (forecast period). The market demand may be influenced by the emergence of cases of rare diseases. The industry will undoubtedly expand due to non-invasive diagnostic techniques like ultrasound therapy. This is supported by the significant healthcare funding that governments provide for their constituents' welfare. Studies relating the condition to eating disorders and a patient's genetic background may be beneficial for the market.

Pharmaceutical corporations and government research institutions both perform clinical studies in an effort to stimulate the market for novel medications and chemicals. For instance, the new chemical RZL-012, which has neither a generic nor a brand name, has been observed to target and induce lipolysis in locations with lipomas. In a jointly performed clinical trial on women by Raziel Therapeutics and the University of Arizona, it demonstrated a fair amount of success.

For patients with diseases, combination therapy may prove to be an effective treatment option. Stem cell therapies and payment arrangements for first prescription drugs may be profitable for pharmaceutical corporations. Partnerships with hospital networks are a further business technique that can aid the global Dercum's disease industry. However a lack of public knowledge of a rare disease can impede its development.

Competitive Outlook

  1. Hoffman-La Roche AG, St. Jude Medical Inc., Eli Lilly and Company, AstraZeneca PLC, Amgen, Johnson Johnson, Merck Co., Inc., Novartis, GlaxoSmithKline Plc, Valeant Pharmaceuticals, Syneron Medical, Abbvie, Inc., Alimed, Inc., and Pfizer, Inc. are some of the noteworthy players in the global Dercum’s disease market.

Segmentation Analysis

The global Dercum’s disease market trends is segmented by treatment, distribution channel, and end-user.

By treatment, it is segmented into acupuncture, surgery, electrotherapy, medication, liposuction, and others. Electrotherapy can show the way for effective treatment for patients with the debilitating disease. Frequency rhythmic electrical modulation system (FREMS) and its subsequent success on administration to patients can drive the segment growth till 2023.

By distribution channel, it is segmented into hospital pharmacies, retail pharmacies, and others.

By end-user, it is segmented into ambulatory surgical centers, hospitals, and others.

Regional Analysis

Europe, the Middle East Africa (MEA), Asia Pacific (APAC), and the Americas are regions covered in the Dercum’s disease market report.

The Americas are pegged to dominate the global market due to awareness of the disease by patients with the help of online forums. The large healthcare expenditure and an established healthcare sector with sufficient methods for treatment and diagnosis can propel the regional Dercum’s disease market growth. Large number of research and development activities dedicated for discerning the cause of the disease and development of reimbursement policies can work favorably for the market.

By providing patients with mesotherapy, a procedure that reduces aberrant forms beneath the skin, Europe can increase the value of the market as a whole. Injections of hormones, nonsteroidal anti-inflammatory medications, and other substances are used in the treatment. The market demand can be predicted by large public healthcare spending.

The APAC region can exhibit a commendable CAGR during the forecast period due to inflow of capital for research and development, economies with a well-developed healthcare framework, and high expendable income levels of citizens. Lastly, the MEA region possesses latent potential due to recent establishment of units dedicated for diagnosis and treatment of rare diseases.

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com


Healthcare

394 Blog posts

Comments